RxDoctor Payments Data

Jennifer Snyder, DO

Family Medicine · Chesterfield, MONPI 1992018287

Payments from drug & device makers

$470in general payments, 2019–2025

Across 19 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$114
  • AbbVie$109
  • Sanofi Pasteur Inc.$85
  • Pfizer$58
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$33
  • Novo Nordisk$20
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$470 in reported general payments places this provider in the 50th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$75,166
Medicare patients
210
Services billed
759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$124,798
JardianceEmpagliflozin49$55,512
Tresiba Flextouch U-200Insulin Degludec40$55,102
XareltoRivaroxaban34$27,068
Repatha SureclickEvolocumab35$23,796
OzempicSemaglutide21$19,554
MounjaroTirzepatide11$18,009
JentaduetoLinagliptin/Metformin Hcl27$16,410
VascepaIcosapent Ethyl40$15,695
Repatha SyringeEvolocumab12$15,434
FarxigaDapagliflozin Propanediol21$15,097
JanuviaSitagliptin Phosphate14$10,912
SymbicortBudesonide/Formoterol Fumarate24$6,938
BrilintaTicagrelor12$5,329
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$5,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$124,798136 claims
AstraZenecaFarxiga, Symbicort, Brilinta, Nexium$14$31,15369 claims
Novo NordiskOzempic$20$19,55421 claims
AbbVieSynthroid$109$1,95428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →